Heerlen polymorphism associated with type III protein S deficiency and factor V Leiden mutation in a Polish patient with deep vein thrombosis

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
Ewa WypasekA Undas

Abstract

Protein S is one of the major natural anticoagulants. A missense serine 501 to proline (S501P) Heerlen polymorphism is associated with reduced levels of free protein S. Heerlen polymorphism, especially when combined with other thrombophilia risk factors, can lead to thromboembolic complications. To our knowledge, we report here the first Polish case associated with heterozygous Heerlen polymorphism resulting in type III protein S deficiency, detected in a 50-year-old man with several thrombotic episodes of deep and superficial veins and a highly positive thrombotic family history. The patient also had factor V Leiden mutation and persistently elevated anticardiolipin antibodies. It seems that increased risk of thrombotic complications could be explained in the patient by a synergy between the effects of Heerlen polymorphism, factor V Leiden heterozygous status and antiphospholipid syndrome.

References

Aug 16, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Cécile V DenisPeter J Lenting
Sep 13, 2007·Thrombosis and Haemostasis·Pablo García de FrutosNúria Sala
Oct 1, 2010·Journal of Thrombosis and Haemostasis : JTH·M Alhenc-GelasUNKNOWN Geht Genetic Thrombophilia Group
Mar 20, 2012·Thrombosis Research·Sameera PeraramelliTilman M Hackeng

❮ Previous
Next ❯

Citations

Jan 4, 2018·Blood Advances·Eun-Ju LeeAlfred Ian Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.